Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,912 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06340568RecruitingPhase 3
Study of an experimental drug vs. chemo for recurring uterine cancer
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
New Haven, ConnecticutAges 18 years+ - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Hot Springs, ArkansasAges 18–55 - NCT05652348Recruiting
Predicting outcomes after heated chemotherapy for stomach or colon spread
This study tries to better predict how well patients do after heated chemotherapy placed in the abdomen during surgery for stomach or colon cancer that has spread to the lining of the abdomen. It may help doctors choose the best treatment plan and timing for future patients.
BerlinAges 18 years+ - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+ - NCT06459271Recruiting
CALM counseling for advanced ovarian cancer
This trial is testing a type of counseling called CALM (Managing Cancer and Living Meaningfully) for people with advanced ovarian cancer. It aims to see if this support program is helpful and practical for patients.
Toronto, OntarioAges 18 years+ - NCT06929286RecruitingPhase 3
Gene therapy vs standard care for bladder cancer after BCG fails
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
Baltimore, MarylandAges 21 years+ - NCT06150417RecruitingPhase 2
Study of extra radiation for prostate cancer spread to few spots
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
New York, New YorkAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT07139990RecruitingPhase 1
Personalized radiotherapy for lung, brain, sarcoma, or head and neck cancers
This trial tests whether giving personalized radiotherapy alongside standard treatments can better control several types of cancer: small cell lung cancer, brain metastases, soft tissue sarcoma, and head and neck cancer. It aims to see if this approach helps patients live longer without their cancer growing or coming back.
Dallas, TexasAges 18 years+ - NCT06358573RecruitingPhase 2
Injecting INT230-6 then immunochemo before surgery for early TNBC
This trial tests a two-step approach: first, an injection of the drug INT230-6 directly into the breast tumor, followed by a combination of immunotherapy and chemotherapy before surgery. The goal is to see if this sequence can shrink or eliminate the cancer more effectively, potentially allowing for a less extensive surgery.
LyonAges 18 years+ - NCT05126472RecruitingPhase 1/Phase 2
Study of 2141-V11 for bladder cancer that did not respond to standard treatment
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT07543536RecruitingPhase 3
Megestrol Acetate for Fatigue in HER2+ Breast Cancer
This study tests whether a medication called megestrol acetate can help reduce severe tiredness and fatigue in people with advanced breast cancer who are receiving a targeted therapy called T-DXd (trastuzumab deruxtecan). Fatigue is a common side effect that can really impact quality of life.
Guangzhou, GuangdongAges 18–75 - NCT07763197Recruiting
Sample collection for bladder cancer research
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
Austin, TexasAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06910072Enrolling by invitationPhase 2/Phase 3
Chemo and immunotherapy before surgery for triple-negative breast cancer
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
BeijingAges 18–75 - NCT05946577Recruiting
Links tinnitus and hearing changes after head and neck cancer treatment
This study looks at how tinnitus (ringing in the ears) and hearing problems may develop after radiotherapy alone or with certain chemotherapy for high-risk head and neck cancer. The goal is to better understand who is more likely to experience these side effects.
ParisAges 18 years+ - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT07718243RecruitingPhase 1/Phase 2
Combining two immunotherapies for solid tumors, melanoma, and lung cancer
This trial tests a new drug (bexmarilimab) plus nivolumab (an approved immunotherapy) for people with advanced solid tumors, melanoma, or non-small cell lung cancer (NSCLC) that has stopped responding to standard treatments.
ManchesterAges 18 years+ - NCT07736937RecruitingPhase 1/Phase 2
Study of TUB-040 with Standard Drugs for Ovarian Cancer
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07162714RecruitingPhase 2
Short-course radiation plus AK112 for mismatch repair-proficient rectal cancer
This trial tests a new immunotherapy drug (AK112) given after a short course of radiation. It is for people with a specific type of mid-low rectal cancer that has not spread and has not been treated before.
Hangzhou, ZhejiangAges 18–75 - NCT06386887Recruiting
Fasting During Chemotherapy for Ovarian Cancer
This trial tests whether adding periods of fasting to standard chemotherapy before surgery helps people with advanced ovarian cancer. It is for those receiving platinum-based chemo for the first time or after recurrence.
Cleveland, OhioAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06830889RecruitingPhase 3
BL-M07D1 vs T-DM1 for HER2-positive breast cancer after neoadjuvant therapy
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06534814Recruiting
AI tool to find lymph node spread in gastric cancer
This trial is testing a new artificial intelligence (AI) model to help doctors better identify whether gastric cancer has spread to nearby lymph nodes. If you qualify, you may help improve how this cancer is diagnosed and treated, without any extra invasive procedures.
Shijiazhuang, HebeiAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,912 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.